LIBERVANT Trademark

Trademark Overview


On Tuesday, November 10, 2020, a trademark application was filed for LIBERVANT with the United States Patent and Trademark Office. The USPTO has given the LIBERVANT trademark a serial number of 90309531. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Thursday, June 20, 2024. This trademark is owned by Aquestive Therapeutics, Inc.. The LIBERVANT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of neurological, cardiopulmonary, viral, metabolic, endocrine, musculoskeletal, genitourinary, gastrointestinal, oncological, autoimmune, inflammatory, pain, respiratory, hormonal, central nervous system, and psychiatric related diseases and disorders; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for treatment of diseases and disorders of the central nervous system; pharmaceutical preparations for the treatment of epilepsy, anxiety disorders, seizure disorders, sleep disorders, insomnia, alcohol, opiate and benzodiazepine withdrawal syndrome, muscle spasms, and psychiatric disorders; pharmaceutical preparations, namely, anticonvulsants, antiseizure medications, psychotropics, benzodiazepines, sedatives, muscle relaxants, and mood stabilizing medications
libervant

General Information


Serial Number90309531
Word MarkLIBERVANT
Filing DateTuesday, November 10, 2020
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateThursday, June 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 27, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of neurological, cardiopulmonary, viral, metabolic, endocrine, musculoskeletal, genitourinary, gastrointestinal, oncological, autoimmune, inflammatory, pain, respiratory, hormonal, central nervous system, and psychiatric related diseases and disorders; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for treatment of diseases and disorders of the central nervous system; pharmaceutical preparations for the treatment of epilepsy, anxiety disorders, seizure disorders, sleep disorders, insomnia, alcohol, opiate and benzodiazepine withdrawal syndrome, muscle spasms, and psychiatric disorders; pharmaceutical preparations, namely, anticonvulsants, antiseizure medications, psychotropics, benzodiazepines, sedatives, muscle relaxants, and mood stabilizing medications

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, January 9, 2021
Primary Code005
First Use Anywhere DateMonday, April 29, 2024
First Use In Commerce DateMonday, April 29, 2024

Trademark Owner History


Party NameAquestive Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWarren, NJ 07059

Party NameAquestive Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWarren, NJ 07059

Trademark Events


Event DateEvent Description
Friday, November 13, 2020NEW APPLICATION ENTERED
Saturday, January 9, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 15, 2021ASSIGNED TO EXAMINER
Friday, March 19, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 7, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 27, 2021PUBLISHED FOR OPPOSITION
Tuesday, April 27, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 22, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 16, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, November 16, 2021SOU EXTENSION 1 FILED
Tuesday, November 16, 2021SOU EXTENSION 1 GRANTED
Thursday, November 18, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 31, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, May 31, 2022SOU EXTENSION 2 FILED
Tuesday, May 31, 2022SOU EXTENSION 2 GRANTED
Thursday, June 2, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 25, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, August 25, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, August 25, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, August 25, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, December 14, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, December 14, 2022SOU EXTENSION 3 FILED
Wednesday, December 14, 2022SOU EXTENSION 3 GRANTED
Friday, December 16, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 30, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 30, 2023SOU EXTENSION 4 FILED
Tuesday, May 30, 2023SOU EXTENSION 4 GRANTED
Thursday, June 1, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 13, 2023SOU EXTENSION 5 FILED
Monday, November 13, 2023SOU TEAS EXTENSION RECEIVED
Saturday, November 25, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, November 25, 2023SOU EXTENSION 5 GRANTED
Tuesday, November 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 18, 2024USE AMENDMENT FILED
Tuesday, June 18, 2024TEAS STATEMENT OF USE RECEIVED
Thursday, June 20, 2024STATEMENT OF USE PROCESSING COMPLETE